Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has successfully raised $22.5 million through a placement to institutional and sophisticated investors, and is launching a $15 million Share Purchase Plan (SPP) for existing shareholders. The funds will support the azer-cel program’s pivotal clinical trial and extend the company’s funding runway into mid-2027, enhancing its operational stability and market positioning.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical stage immuno-oncology company based in Sydney, Australia. The company focuses on developing innovative cancer immunotherapies, with a particular emphasis on advancing its azer-cel program.
Average Trading Volume: 558,515
Technical Sentiment Signal: Sell
Current Market Cap: A$93.35M
Learn more about IMU stock on TipRanks’ Stock Analysis page.